Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

Cite this

@article{dbb951257e7a4229be6b113f807e11dd,

title = "Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity",

author = "Maria Rovithi and Verheul, {Henk M.W.}",

year = "2017",

month = "8",

day = "1",

doi = "10.1007/s10456-017-9555-8",

language = "English",

volume = "20",

pages = "287--289",

journal = "Angiogenesis",

issn = "0969-6970",

publisher = "Springer Netherlands",

number = "3",

}

TY - JOUR

T1 - Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity

AU - Rovithi, Maria

AU - Verheul, Henk M.W.

PY - 2017/8/1

Y1 - 2017/8/1

UR - http://www.scopus.com/inward/record.url?scp=85017638734&partnerID=8YFLogxK

U2 - 10.1007/s10456-017-9555-8

DO - 10.1007/s10456-017-9555-8

M3 - Letter

C2 - 28421290

AN - SCOPUS:85017638734

VL - 20

SP - 287

EP - 289

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 3

ER -